Trial Profile
Phase I Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 12 Jan 2015
Price :
$35
*
At a glance
- Drugs Glesatinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Mirati Therapeutics
- 12 Jan 2015 New trial record